|
Sign In to gain access to subscriptions and/or personal tools.
|
Relief of Left Ventricular Outflow Obstruction by Cibenzoline in a Patient With Fabry’s Disease
A Case Report
Shin-ichiro Morimoto, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan, morimoto{at}fujita-hu.ac.jp
Atsushi Sugiura, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Masatsugu Iwase, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Natsuko Kubo, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Shinya Hiramitsu, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Akihisa Uemura, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Masatsugu Ohtsuki, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Shigeru Kato, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Yasuchika Kato, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
Hitoshi Hishida, MD
Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan
A 46-year-old man was admitted for further evaluation of exertional chest discomfort. One family member had experienced sudden death, and 2 others had died of heart failure, including 1 known to have had Fabry’s disease. The patient was also diagnosed with Fabry’s disease, based on reduced leukocyte a-galactosidase A activity, 2.0 nmol/mg protein/hour, as well as endomyocardial biopsy findings of marked sarcoplasmic vacuolization of cardiac muscle cells by light microscopy and lamellated "zebra bodies" in the cytoplasm shown by electron microscopy. Echocardiography disclosed marked left ventricular hypertrophy and systolic anterior motion of the mitral leaflets. On cardiac catheterization, a left ventricular peak systolic outflow gradient of 50 mm Hg was noted; this decreased to 10 mm Hg following intravenous administration of 100 mg of cibenzoline. It is imperative to recognize the existence of cases with Fabry’s disease associated with left ventricular outflow obstruction.
References
- Grabowski GA: Lysosomal storage diseases. In: Harrison’s Principles of Internal Medicine, vol. 2. ed. 15, ed. by Braunwald Eet al. New York: McGraw-Hill, 2001, pp 2276-2281.
- Desnick RJ, Ioannou YA, Eng CM: a-galactosidase A deficiency. In: Fabry Disease. The Metabolic and Molecular Bases of Inherited Disease, ed. by Scriver CRet al. New York: McGraw-Hill, 1995, pp 2741-2784.
- Ferrans VJ, Hibbs RG, Burda CD: The heart in Fabry’s disease. Am J Cardiol 24:95-110, 1969.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bradbent JC, Edwards WD, Gordon H, et al: Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. Mayo Clin Proc 56:623-628, 1981.[Web of Science][Medline]
[Order article via Infotrieve]
- Tanaka H, Adachi K, Yamashita Y, et al: Four cases of Fabry’s disease mimicking hypertrophic cardiomyopathy. J Cardiol 18:705-718, 1988 (in Japanese with English abstract).[Medline]
[Order article via Infotrieve]
- Fritz P, Schneider H, Heimburg P, et al: Sekundäre hypertrophe obstruktive Kardiomyopathie bei Morbus Fabry. Med Welt 29:1851-1854, 1978.[Web of Science][Medline]
[Order article via Infotrieve]
- Colucci WS, Lorell BH, Schoen FJ, et al: Hypertrophic obstructive cardiomyopathy due to Fabry’s disease. N Engl J Med 307:926-928, 1982.[Web of Science][Medline]
[Order article via Infotrieve]
- Nakayama Y, Tsumura K, Yamashita N, et al: Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry’s disease improved following implantation of a dual chamber pacemaker. Pace 22:1114-1115, 1999.
- Nakao S, Takenaka T, Maeda M, et al: An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293, 1995.[Abstract/Free Full Text]
- Ommen SR, Nishimura RA, Edwards WD: Fabry disease: A mimic for obstructive hypertrophic cardiomyopathy? Heart 89:929-930, 2003.[Free Full Text]
- Shah PM, Gramiak R, Kramer DH: Ultra-sound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 40:3-11, 1969.[Abstract/Free Full Text]
- Ross J Jr, Braunwald E, Gault JH, et al: The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation 34:558-578, 1966.[Free Full Text]
- Klues HG, Robert WC, Maron BJ, et al: Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Circulation 84:1188-1197, 1991.[Abstract/Free Full Text]
- Jiang L, Levine RA, King ME, et al: An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 113: 633-644, 1987.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Klues HG, Robert WC, Maron BJ: Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 87:1570-1579, 1993.[Abstract/Free Full Text]
- Levine RA, Vlahakes GJ, Lefebvre X, et al: Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 91:1189-1195, 1995.[Abstract/Free Full Text]
- Hamada M, Shigematsu Y, Ikeda S, et al: Class Ia antiarrhythmic drug cibenzoline. A new approach to the treatment of hypertrophic obstructive cardiomyopathy. Circulation 96:1520-1524, 1997.[Abstract/Free Full Text]
- Hamada M, Shigematsu Y, Hara Y, et al: Anti-arrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 65:531-538, 2001.[CrossRef][Medline]
[Order article via Infotrieve]
- Maron BJ, Casey SA, Poliac LC, et al: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650-655, 1999.[Abstract/Free Full Text]
- Weidemann F, Breunig F, Beer M, et al: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 108:1299-1301, 2003.[Abstract/Free Full Text]
Angiology, Vol. 57, No. 2,
241-245 (2006)
DOI: 10.1177/000331970605700217
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
